1. Home
  2. EDIT vs LPTX Comparison

EDIT vs LPTX Comparison

Compare EDIT & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDIT
  • LPTX
  • Stock Information
  • Founded
  • EDIT 2013
  • LPTX 2011
  • Country
  • EDIT United States
  • LPTX United States
  • Employees
  • EDIT N/A
  • LPTX N/A
  • Industry
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • EDIT Health Care
  • LPTX Health Care
  • Exchange
  • EDIT Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • EDIT 108.1M
  • LPTX 119.6M
  • IPO Year
  • EDIT 2016
  • LPTX N/A
  • Fundamental
  • Price
  • EDIT $1.92
  • LPTX $0.48
  • Analyst Decision
  • EDIT Buy
  • LPTX Buy
  • Analyst Count
  • EDIT 14
  • LPTX 3
  • Target Price
  • EDIT $8.08
  • LPTX $8.50
  • AVG Volume (30 Days)
  • EDIT 5.8M
  • LPTX 1.5M
  • Earning Date
  • EDIT 03-03-2025
  • LPTX 03-17-2025
  • Dividend Yield
  • EDIT N/A
  • LPTX N/A
  • EPS Growth
  • EDIT N/A
  • LPTX N/A
  • EPS
  • EDIT N/A
  • LPTX N/A
  • Revenue
  • EDIT $61,759,000.00
  • LPTX N/A
  • Revenue This Year
  • EDIT N/A
  • LPTX N/A
  • Revenue Next Year
  • EDIT N/A
  • LPTX N/A
  • P/E Ratio
  • EDIT N/A
  • LPTX N/A
  • Revenue Growth
  • EDIT 150.95
  • LPTX N/A
  • 52 Week Low
  • EDIT $1.12
  • LPTX $0.47
  • 52 Week High
  • EDIT $11.58
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • EDIT 55.72
  • LPTX 19.00
  • Support Level
  • EDIT $1.12
  • LPTX $0.47
  • Resistance Level
  • EDIT $3.30
  • LPTX $0.53
  • Average True Range (ATR)
  • EDIT 0.30
  • LPTX 0.04
  • MACD
  • EDIT 0.12
  • LPTX 0.07
  • Stochastic Oscillator
  • EDIT 36.70
  • LPTX 7.42

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: